Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1381-1385

  Kilickap, Saadettin ^a   Kaya, Yalcin ^b   Yucel, Birsen ^b   Tuncer, Ersin ^b   Babacan, Nalan Akgul ^b   Elagoz, Sahande ^c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c NONE

Author keywords

Breast cancer; Her2; Hormone receptor; Ki67 expression; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; AXILLA; BIOSYNTHESIS; BREAST TUMOR; CANCER GRADING; CELL PROLIFERATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR INVASION; TUMOR RECURRENCE;

AXILLA; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84896884114     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1381     Document Type: Article

References (31)

1. Beresford MJ, Wilson GD, Makris A (2006). Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res, 8, 216.
2. Bottini A, Berruti A, Bersiga A, et al (2001). Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer, 85, 1106-12.
3. Colozza M, Azambuja E, Cardoso F, et al (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol, 16, 1723-39.
4. de Azambuja E, Cardoso F, de Castro G Jr, et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer, 96, 1504-13.
5. DeCensi A, Guerrieri-Gonzaga A, Gandini S, et al (2011). Prognostic significance of Ki-67 labeling index after shortterm presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol, 22, 582-7.
6. Dowsett M, Smith IE, Ebbs SR, et al (2007). Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst, 99, 167-70.
7. Dowsett M, Smith IE, Ebbs SR, et al (2006). IMPACT Trialists Group. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res, 12, 1024-30
8. Ellis MJ, Tao Y, Luo J, et al (2008). Outcome prediction for estrogen receptorpositive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst, 100, 1380-8.
9. Fabian CJ, Kimler BF, Zalles CM, et al (2007). Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat, 106, 75-84.
10. Faratian D, Munro A, Twelves C, Bartlett JMS (2009). Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology, 54, 254-7
11. Gasparini G, Pozza F, Meli S, et al (1991). Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki67 and correlation with fl ow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res, 11, 2015-21.
12. Gerdes J, Lemke H, Baisch H, et al (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol, 133, 1710-5.
13. Gudlaugsson E, Klos J, Skaland I, et al (2013). Prognostic comparison of the proliferation markers mitotic activity index, phosphohistone H3, Ki67, steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T1-2N0M0 breast cancer. Pol J Pathol, 64, 1-8.
14. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC Curves for Censored Survival Data and a Diagnostic Marker, Biometrics, 56, 337-44
15. Heidebrecht HJ, Buck F, Haas K, Wacker HH, Parwaresch R (1996). Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki67'proteins. Cell Prolif, 29, 413-25.
16. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat,139, 539-52
17. Jalava P, Kuopio T, Juntti-Patinen L, et al (2006). Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassifi cation: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology, 48, 674-82.
18. Jemal A, Bray F, Center MM, et al (2011) Global cancer statistics. CA Cancer J Clin, 61, 69-90.
19. Jones RL, Salter J, A'Hern R, et al (2009). The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat, 116, 53-68.
20. Klintman M, Bendahl PO, Grabau D, et al; South Sweden Breast Cancer Group (2010). The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol, 23, 251-9.
21. Sahin AA, Ro J, Ro JY, et al (1991). Ki67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer, 68, 549-57.
22. Spyratos F, Ferrero-Pous M, Trassard M, et al (2002). Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer, 94, 2151-9
23. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008). Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients. Breast, 17, 323-34.
24. Talley LI, Grizzle WE, Waterbor JW, et al (2002). Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre-and postmenopausal women. Int J Cancer, 98, 118-27
25. Tan PH, Bay BH, Yip G, et al (2005). Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol, 18, 374-81
26. Tanei T, Shimomura A, Shimazu K, et al (2011). Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol, 37, 155-61
27. Untch M, Gerber B, Möbus V, et al (2011). Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011). Breast Care, 6, 144-52.
28. Urruticoechea A, Smith IE, Dowsett M (2005). Proliferation marker Ki-67 in early breast cancer. J Clin Oncol, 23, 7212-20.
29. van Diest PJ, van der WE, Baak JP (2004). Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol, 57, 675-81
30. Viale G, Regan MM, Mastropasqua MG, et al; International Breast Cancer Study Group (2008). Predictive value of tumor Ki67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst, 100, 207-12
31. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83